Federal Coverage Of COVID Drugs Is Ending

COVID-19 treatments, including Pfizer’s Paxlovid, will begin transitioning to the commercial market this week, with costs of the drugs set to increase.

Why it matters: The oral antivirals reduce the risk of hospitalization or death from COVID-19 and until now have been free for patients through the federal government. The Biden administration and drugmakers have taken steps to ensure access to the treatments after they move to the commercial market.

Details: The shift begins Nov. 1., when Pfizer and Merck, which makes the lesser-used treatment Lagevrio, begin to distribute their antivirals through traditional channels.

  • Millions of free doses procured by the federal government will likely be available across the country in hospitals, doctor’s offices and pharmacies for a short time until those treatments run out, federal officials say.

Between the lines: It’s still unclear how much commercially insured patients will pay for the drugs through co-pays.

  • Pfizer has said it will price Paxlovid at $1,390 per five-day course, more than double what the federal government paid. That price does not reflect any rebates or negotiated discounts.
  • Merck has not yet confirmed the list price for Lagevrio, per the Associated Press.

Zoom in: The uninsured, and those with Medicare or Medicaid coverage, will be able to get Paxlovid at no cost until the end of 2024.

  • Pfizer is also setting up a patient-assistance program for uninsured and underinsured people, and it will run a co-pay savings program for those with private insurance.
  • Officials say they also expect Merck’s patient assistance program will help certain patients.
  • Federal entities including the Indian Health Service, the Department of Veterans Affairs and the Department of Defense will retain access to federally acquired Paxlovid.

What’s next: Following a bumpy transition of COVID vaccines to the commercial market, the transition of COVID drugs will be closely watched.

  • “It is of paramount importance that these medications remain widely accessible to high-risk patients after commercial distribution begins in order to minimize hospitalizations and deaths from COVID-19,” Health and Human Services Secretary Xavier Becerra said in a letter to manufacturers and distributors on Friday.

 

Source Link

Recommended Articles

State PBM laws Face ERISA Preemption Challenges in Court

States seeking to limit the power of pharmacy benefit managers are running into legal roadblocks. Every state, as well as the federal government, has enacted PBM legislation over the last decade to rein in an industry accused of anticompetitive business practices. Those efforts have seen mixed results as agencies struggle to enforce requirements and courts ...

Read More

Employer Health Cost Crunch Is Worse Than Projected

There’s new evidence that double-digit health cost increases were hitting employers well before the forecasts of big spikes for 2027 — forcing big changes in workplace coverage for millions of Americans. Why it matters: The findings offer a higher-resolution view of how much health spending is putting a drag on the labor market and increasing ...

Read More

HHS Finalizes Changes To HIPAA Privacy Rule

HHS' Office for Civil Rights finalized a HIPAA privacy rule change cutting the protected health information request response window to 15 calendar days. The final regulation clarifies individuals can retrieve electronic PHI through health apps when entities can support that format.

Read More

Sutter Health-Allina Health Deal Clears Key Hurdle

Sutter Health and Allina Health have achieved a milestone in their plan to merge. The health systems agreed to invest $2.15 billion as part of a 10-year oversight arrangement that Minnesota Attorney General Keith Ellison (D) announced Monday. The deal has been under state review for months. Under terms of the agreement, Sacramento, California-based Sutter ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square